Shares of Johnson & Johnson (NYSE:JNJ) ended Wednesday session in red amid volatile trading. The shares closed down -0.48 points or -0.42% at $114.86 with 6.59 million shares getting traded. Post opening the session at $115.52, the shares hit an intraday low of $114.83 and an intraday high of $115.76 and the price vacillated in this range throughout the day. The company has a market cap of $312.48 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
Johnson & Johnson (JNJ) recently declared the launch of the Africa Innovation Challenge, an program to support Africa’s vibrant and growing innovation ecosystem and to assist develop important and locally sustainable consumer health solutions. The challenge is the most recent program in the company’s comprehensive approach to advancing health and innovation worldwide. The Johnson & Johnson Family of Companies’ presence in Africa dates back more than 80 years and includes business operations, public health programs and corporate citizenship.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) ended Wednesday session in red amid volatile trading. The shares closed down -0.23 points or -0.45% at $50.57 with 8.20 million shares getting traded. Post opening the session at $50.93, the shares hit an intraday low of $50.53 and an intraday high of $50.98 and the price vacillated in this range throughout the day. The company has a market cap of $84.33 billion and the numbers of outstanding shares have been calculated to be 1.67 billion shares.
Bristol-Myers Squibb Co (BMY) recently declared new data evaluating the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) and Opdivo plus new investigational Immuno-Oncology assets, counting lirilumab, will be presented at the 2016 Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting from November 9 – 11 in National Harbor, Maryland. These presentations underscore Bristol-Myers Squibb’s dedication to investigating complementary Immuno-Oncology compounds that target different immune system pathways, counting the ongoing study of Opdivo and Yervoy, with the aim of discovering transformational combinations that may offer the most noteworthyimprovements in overall survival and address areas of high unmet patient need.